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Abstract
Introduction: Adipose tissue is responsible for triggering chronic systemic inflammatory response and these changes may
be involved in the pathophysiology of preeclampsia.
Objective: To characterize the lipid profile in the placenta and plasma of patients with preeclampsia.
Methodology: Samples were collected from placenta and plasma of 10 pregnant women with preeclampsia and 10
controls. Lipids were extracted using the Bligh–Dyer protocol and were analysed by MALDI TOF-TOF mass spectrometry.
Results: Approximately 200 lipid signals were quantified. The most prevalent lipid present in plasma of patients with
preeclampsia was the main class Glycerophosphoserines-GP03 (PS) representing 52.30% of the total lipid composition,
followed by the main classes Glycerophosphoethanolamines-GP02 (PEt), Glycerophosphocholines-GP01 (PC) and
Flavanoids-PK12 (FLV), with 24.03%, 9.47% and 8.39% respectively. When compared to the control group, plasma samples
of patients with preeclampsia showed an increase of PS (p,0.0001), PC (p,0.0001) and FLV (p,0.0001). Placental analysis
of patients with preeclampsia, revealed the PS as the most prevalent lipid representing 56.28%, followed by the main class
Macrolides/polyketides-PK04 with 32.77%, both with increased levels when compared with patients control group, PS (p,
0.0001) and PK04 (p,0.0001).
Conclusion: Lipids found in placenta and plasma from patients with preeclampsia differ from those of pregnant women in
the control group. Further studies are needed to clarify if these changes are specific and a cause or consequence of
preeclampsia.
Citation: Korkes HA, Sass N, Moron AF, Caˆmara NOS, Bonetti T, et al. (2014) Lipidomic Assessment of Plasma and Placenta of Women with Early-Onset
Preeclampsia. PLoS ONE 9(10): e110747. doi:10.1371/journal.pone.0110747
Editor: Pascale Chavatte-Palmer, INRA, France
Received May 1, 2014; Accepted September 25, 2014; Published October 17, 2014
Copyright:  2014 Korkes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: Funding provided by National Council for Scientific and Technological Development; CNPq Number: 476486/2011-4, http://www.cnpq.br/en and
Foundation for Research Support of the State of Sa˜o Paulo; FAPESP Number: 12/02270-2, http://www.fapesp.br/en/. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: korkes@me.com
Introduction
Preeclampsia is a systemic disease characterized by intense
inflammatory response, endothelial injury, platelet aggregation,
coagulation system activation and increase vascular resistance. It
affects about 5–8% of all pregnant women [1–3]. The diagnosis of
preeclampsia is based on the development of hypertension ($140/
90 mmHg) and significant proteinuria ($300 mg/24 hours) after
20 weeks of gestation [4].
The systemic complications of preeclampsia are not limited to
the gestational period and recent studies have shown long-term
adverse outcomes, such as increased risk for developing chronic
hypertension, ischemic heart disease, acute myocardial infarction
and venous thromboembolism, requiring longer follow-up and
surveillance of these patients throughout their lives [4,5]. Despite
its relevance, preeclampsia pathogenesis is not completely
understood. It has been established that the trophoblast has a
key role in this process and many other conditions related to
chronic inflammation can be relevant in different stages of the
disease [3].
Obesity and Preeclampsia
Obesity, defined by the World Health Organization (WHO)
through the body mass index above 30 kg/m2, is a growing
epidemic problem and it affects 500 million adults across the world
[6,7]. It represents an important health problem and it has an
enormous impact on modern obstetrics.
Adipose tissue is responsible for triggering chronic systemic
inflammatory response, with increased levels of inflammatory
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cytokines such as TNF-a, IL-6 and MCP-1. The inflammatory
response related to obesity has been considered as the link between
this condition and preeclampsia [6,8–13].
Although the link between obesity and inflammatory response is
well recognized, the roles of lipids in the cell function are even
more extended. These molecules are responsible for the control of
important cellular processes, including proliferation, apoptosis,
metabolism and migration. They also assist in the transmission of
biological information across cell membranes, directly contribut-
ing to proper cell functioning [14–16]. An impairment in lipid
signaling pathways may contribute to the progression of chronic
inflammatory diseases, such as autoimmune, allergic, neoplastic,
atherosclerosis, hypertension, myocardial hypertrophy and meta-
bolic degenerative diseases [17,18] and may be also related to
preeclampsia pathophysiology.
Lipid molecules are defined by the International Committee for
the Classification and Nomenclature of Lipids (ICCNL) in eight
categories, based on their chemical functions: Fatty Acyls (FA),
Glycerolipids (GL), Glycerophospholipids (GP), Sphingolipids
(SP), Sterol Lipids (ST), Prenol Lipids (PR), Saccharolipids (SL)
and Polyketides (PK). Each category is further subdivided into
lipid main classes and subclasses [19,20].
Historically, the study of the function and properties of lipids
was always extremely complicated due to their structural diversity
and large number of isomorphic species. Technically, the
distinction between pathogenic and nonpathogenic lipid molecules
represents a challenge that has become possible through lipidomics
[18,21,22].
Lipidomic analysis
Lipidomic analysis is a global characterization of all kinds of
lipid molecules in biological system. The methodology used is mass
spectrometry (MS) [22–24]. A technique known as Matrix-Assisted
Laser Desorption/Ionization - Mass Spectrometry (MALDI-MS),
has been the preferred method to evaluate lipidomics because it is
relatively easy to handle [25,26]. MALDI is an ionization
technique enabled by a laser beam (light amplification by
stimulated emission of radiation) that acts upon a sample mixed
with a matrix. This process generates ionized molecules. For
complete separation, the most widely used technology is the time
of flight (TOF), which consists of a long pipe (tube flight) capable
of separating the ionized molecules according to a ratio of mass to
charge (m/z) [25].
Lipidomic analysis in preeclampsia is a new research line.
Recently, we demonstrated that women with early-onset pre-
eclampsia have particular lipids in their plasma when compared to
those with healthy pregnancy [26]. Additionally, Baig et al.
published their findings evaluating samples of syncytiotrophoblast
microvesicles from human placenta [27]. These authors also
demonstrated that there was a significant increase of some classes
of lipids as well as a reduction of others in samples from
preeclamptic women.
Given the strong association between obesity and early
dyslipidemia with preeclampsia and the first reports associating
distinct lipid species with the disease, this study aimed to find a
specific lipid profile that may be characteristic for these patients.
Here we evaluated plasma samples and placental tissues of women
with early-onset preeclampsia and established an interesting panel
of lipids in these different settings.
Material and Methods
Ethics Statement
All participants in this study have provided their written
informed consent. This study was approved by the Research
Ethics Committee of the Federal University of Sa˜o Paulo with the
number 297/027 and by the Research Ethics Committee of the
School Maternity Vila Nova Cachoeirinha with the number 34/
2011, linked with the National database (CEP/CONEP) under the
protocol number CAAE - 18100813.1.0000.5505.
Study Population
This is a case-control study involving 20 pregnant women (10
women with early-onset preeclampsia and 10 women with healthy
pregnancy). All samples were collected at the School Maternity
Vila Nova Cachoeirinha from October 2011 to April 2013. Early-
onset preeclampsia was defined as blood pressure $140/
90 mmHg and significant proteinuria ($300 mg/24 hours) after
20 weeks of gestation and before 34 weeks.
Sample collection
Blood. Five milliliters of peripheral blood were drawn in
EDTA-tube at the time of delivery. Immediately after collection,
blood samples were centrifuged at 2000 rpm for 5 minutes and
supernatants aliquoted and stored at 280uC for subsequent lipid
extraction.
Placenta. Immediately after cesarean delivery, one fragment
was removed from the central region of the basal plate of the
placenta, with a wedge shape of approximately 3.0 cm in diameter
at its greatest diameter, obtained with a sterile scalpel blade Nu15.
This fragment was divided in 3 smaller pieces of 161 cm, washed
in saline solution and immediately frozen and stored at 280uC for
further processing and lipid extraction. For lipid extraction the
frozen placental sample of 161 cm was plunged into liquid
nitrogen for 1 minute and crushed using marble stone until
obtaining small fragments (powder). Powder was then placed in a
dry tube containing 300 ml of Milli-Q water. This material was
subjected to further mixing and homogenization in a mechanical
processor for five minutes and the resulting material subjected to
lipid extraction.
Lipid extraction
Lipids were extracted from each sample using the Bligh–Dyer
protocol [28]. Immediately after thawing, each 50 mL of plasma
and placental homogenated (described above) were dissolved in a
mixture of chloroform–methanol (125:250 mL) and vortexed well.
After vortexing, 125 mL of chloroform and 100 mL of deionized
water were added to supernatant and centrifuged at 1000 rpm in a
table-top centrifuge for 5 min at room temperature. Following this
protocol a two-phase system (aqueous top, organic bottom) was
achieved. The bottom phase containing lipids was gently
recovered using a Pasteur pipette; they were dried and sealed to
be stored at 280uC.
Reagents
All chemicals were of analytical reagent grade and they were
used as received. Chloroform (CHCl3) and methanol (MeOH)
were purchased from Burdick & Jackson (Muskegon, MI, USA).
2,5-Dihydroxybenzoic acid (DHB) was purchased from ICN
Biomedicals (Aurora, OH, USA). Distilled water was deionized
on a Millipore Milli-Q water reagent system (Millipore, Bedford,
MA, USA). EDTA-tubes were purchased from Sigma-Aldrich (St.
Louis, MO).
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Mass spectrometry analysis
MALDI-MS spectra were acquired in the positive ion and
reflector modes using the equipment MALDI TOF-TOF -
Ultraflex model - Bruker and matrix 2,5 - DHB - White (2,5-
Dihydroxy benzoic acid - 40 mg/ml in acetonitrile). The main
operating condition used was 10 V (sample plate). The laser
irradiation consisted of diverse shots during 60–90 seconds in the
region where the sample had been placed.
Data processing
Raw data were analyzed by MarkerLynx (Waters, UK) for peak
detection and alignment. The parameters were set as follows: mass
tolerance was set at 100 ppm (suggested more than twice the
instrument mass accuracy considering extreme value in signal
saturation condition); peak width at 5% height and peak-to-peak
baseline noise were calculated automatically by the software; mass
window was set at 0.1 amu (atomic mass units); retention time
window was set at 1 min (considering the maximum variation
obtainable by a CapLC system); noise elimination level was 5;
minimum intensity was set at 5%; peak intensity and retention
time were normalized with the signal of the internal standard. This
procedure allowed deconvolution alignment, and data reduction
to give a table of mass and relative retention time pairs with
associated relative intensities for all the detected peaks. Then data
matrix was exported for partial least squares discriminant analysis
(PLS-DA). In order to find differential circulating lipids, a VIP
parameter (Variable Importance in the Projection) was employed
to reflect the variable importance in the discriminant analysis. The
major discriminant variables returned by the PLS-DA model were
selected and underwent the Mann–Whitney U test to confirm the
differential expression between groups. Those peaks showing p,
0.05 were considered as having statistically significant differences.
Statistical Analysis
The lipid composition of the samples was established by the
area of the peaks obtained for the main lipids identified. The data
were normally distributed and statistical analysis was performed
using the Student’s t-test, using the GraphPad Prism version 6.
Differences between the groups were considered statistically
significant when p,0.05.
Results
Table 1 shows the demographic and obstetric characteristics of
study participants.
Mass Spectrometry
Approximately 200 signals were identified between the lipid
tracks acquisition from 600 to 1200 m/z (Figure 1). The
identification of the different lipids found was carried out through
the Lipid Database Search (http://www.lipidmaps.org), using the
results of m/z analyzes.
Plasma samples
Table 2 and Figure 2 show the lipid composition found in
plasma samples from both groups. Plasma analysis of patients with
preeclampsia revealed the main class of Glycerophosphoserines-
GP03 (PS) as the most prevalent lipid, representing 52.30% of the
total lipid composition, followed by Glycerophosphoethanola-
mines-GP02 (PEt), Glycerophosphocholines-GP01 (PC) and
Flavanoids-PK12 (FLV). When compared to the control group,
plasma samples of patients with preeclampsia showed an increased
proportion of PS (p,0.0001), PC (p,0.0001) and FLV (p,
0.0001).
Although in smaller proportion, other increased lipids in
patients with preeclampsia were Glycerophosphates-GP10 (PAc)
(p,0.0001), Phosphosphingolipids-SP03 (SM) (p,0.0001), Neu-
tral glycosphingolipids-SP05 (p,0.0001) and Steroid conjugates-
ST05 (p,0.0002). The main class PEt, was reduced in patients
with preeclampsia when compared to the control group (p,
0.0001). Other main lipid classes reduced in preeclampsia group
were: Glycerophosphoglycerols-GP04 (PG) (p,0.003), Sterols-
ST01 (p,0.0001) and Other acyl sugars-SL05 (p,0.0001).
Placental samples
Table 3 and Figure 3 show the lipid composition found in
placental samples from both groups. The placental analysis of
patients with preeclampsia revealed the main class PS as the most
prevalent lipid, representing 56.28% of the total composition.
Other main classes found were: Macrolides and lactone polyke-
tides-PK04 with 32.77%, both were increased in preeclamptic
placentas when compared to the control group, PS (p,0.0001)
and PK04 (p,0.0001). Some lipids found in placentas from
patients with preeclampsia were reduced when compared to
control group; PEt (p,0.0001), PG (p,0.0001), Glyceropho-
sphoinositols-GP06 (PI) (p,0.0001), Glycerophosphoinositol
monophosphates-GP07 (p,0.0001), Diradylglycerols-GL02 (p,
0.0001), Triradylglycerols-GL03 (p,0.0001), Acidic glycosphin-
golipids-SP06 (GM3) (p,0.0001), Steroid conjugates-ST05 (p,
0.0001), Other acyl sugars-SL05 (p,0.0001) and Flavonoids-
PK12 (p,0.0001).
Discussion
The pathogenesis of preeclampsia has its roots on deficient
trophoblastic invasion and failure in spiral artery remodeling. This
incomplete transformation of the spiral arteries leads to inadequate
placental perfusion and consequently to placental oxidative stress
[29]. The altered placenta then releases great amount of
microparticles, debris and antiangiogenic factors into the maternal
circulation [30–32]. All these factors are supposed to act in synergy
to initiate and to maintain an intense inflammatory response and
an antiangiogenic state.
Maternal obesity has been considered to have important impact
on the genesis of preeclampsia as obese women have higher risk
for developing the disease. In addition, women with body-mass-
index lower than 20 have lower risk to develop preeclampsia [33].
The complete link between preeclampsia and obesity has not been
defined. However, it is known that the inflammatory aspect that
characterize the lipotoxicity of adipose tissues leads to maternal
endothelial dysfunction, decreases trophoblastic invasion and
influences placental metabolism and function. In addition, the
chronic inflammatory response of the ‘‘metabolic syndrome’’ can
contribute to the systemic inflammation seen in preeclampsia [13].
Actually, lipids play important roles in cellular function as they
are the main components of biological membranes [14]. There-
fore, lipids can participate in the constitution of membrane
receptors, ion channels and in cell signaling mechanisms. In
addition, many lipids can act as endogenous ligands, binding to
specific receptors and then initiating several immunological
responses [34].
In this study we investigated and established the main
composition of the lipid profile identified in plasma and placental
tissue of normal pregnant and preeclamptic women. Either
placental tissues or plasma from patients with preeclampsia
expressed different lipid profile when compared to normal
pregnant women. These findings suggest that specific lipid species
may be more associated with risk of developing preeclampsia than
Lipidomic Profile of Women with Early-Onset Preeclampsia
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others. Additional functional studies will be necessary to clarify the
involvement of these lipids in the pathophysiology of preeclampsia.
PS were the most prevalent species of lipids in preeclamptic
women group. These lipids belong to Glicophospholipids category,
representing the major lipid constituent of cell membranes and
lipoproteins. They play different biological roles, acting as
signaling molecules involved in the processes of oxidative stress,
apoptosis and coagulation, all exacerbated in preeclampsia [35–
39].
PC species also belong to Glicophospholipids category and were
increased in plasma of patients with preeclampsia. PC species are
precursors of several molecules that act as lipid second messengers,
including phosphatidic acid. Increased levels of PC have been
associated with increased cell proliferation. These lipids have been
Table 1. Demographic and obstetric characteristics of study subjects.
Control Preeclampsia P
(n=10) (n =10)
Maternal age (years) 25.366.237 22.467.152 0.372
Gestational age (weeks) 38.661.174 35.563.504 0.026
Weight gain (Kg) 10.7765.094 20.2265.037 0.001
BMI (Kg/m2) 22.5966.912 26.7365.379 0.154
Blood Pressure
Systolic (mmHg) 116610.666 140.464.971 ,0.0001
Diastolic (mmHg) 70.667.306 9165.436 ,0.0001
Birth Weights (g) 3190.66581.115 26076881.328 0.0975
Proteinuria (mg) NE 1624.461072.915 NE
Results are expressed as mean 6 standard deviation. Significant at P,0.05.
BMI – Body Mass Index.
NE - not evaluated.
doi:10.1371/journal.pone.0110747.t001
Figure 1. Representative lipid spectrum showing signals in plasma samples of control and preeclamptic patients. The signals were
identified between the lipid tracks acquisition from 600 to 1200 m/z.
doi:10.1371/journal.pone.0110747.g001
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recently correlated with different tumor behaviors and cancer
progressions. They are probably important for treatment consid-
erations [40–42].
Oxidative stress generally affects lipid function due to changes
in their native behavior. It can generate numerous different lipids
that have diverse biological activities [43,44]. Glicerophospholi-
pids, when oxidized, induce platelet aggregation, monocyte
adhesion to endothelial cells, present in atherosclerotic lesions
and they play an important role in signaling inflammatory
response [45,46]. Thus, this increase in PS and PC in preeclamp-
sia suggests a role in the inflammatory and oxidative phenomena
observed in these patients.
There was a curious reduction of PEt in plasma samples of the
preeclampsia group, compared to the control group. Apparently
the reduction of PEt in the endoplasmic reticulum is associated
with araquidonic acid release [47,48]. This is the precursor of
prostaglandins, thromboxanes and prostacyclins by the cycloox-
ygenase pathway and leukotrienes by the lipoxygenase pathway.
Prostaglandins cause vasodilation, inhibition of platelet aggrega-
tion and pain. Thromboxane A2 promotes vasoconstriction and
platelet aggregation. It is possible that these lipids act in opposing
mechanisms in different patients.
Although also associated with apoptotic processes, cell prolifer-
ation and differentiation, the PI lipid class was found in small
amounts in the plasma lipid composition in both groups. The SM
lipid species, found only in plasma samples from patients with
preeclampsia, act in vascular reactivity and mediate cell growth
due to intrinsic properties of these vasoactive species [49].
Table 2. Main classes of lipids in plasma samples.
Plasma Group P
[Main class]-(Common name) Control (n = 10) Preeclampsia (n =10)
Glycerophosphocholines [GP01]-(PC) 0.41% 9.47% ,0.0001
Glycerophosphoethanolamines [GP02]-(PEt) 77.38% 24.03% ,0.0001
Glycerophosphoserines [GP03]-(PS) 15.53% 52.30% ,0.0001
Glycerophosphoglycerols [GP04]-(PG) 3.14% 0.90% 0.003
Glycerophosphoinositols [GP06]-(PI) 0.62% 0.13% NS
Glycerophosphates [GP10]-(PAc) 0.09% 1.40% ,0.0001
CDP-Glycerols [GP13] 0.02% 0.00% NE
Triradylglycerols [GL03]-(TG) 0.22% 0.16% NS
Phosphosphingolipids [SP03]-(SM) 0.00% 0.37% ,0.0001
Neutral glycosphingolipids [SP05] 0.00% 1.72% ,0.0001
Sterols [ST01] 0.31% 0.03% ,0.0001
Steroid conjugates [ST05] 0.00% 0.65% 0.0002
Polyprenols [PR03] 0.02% 0.00% NE
Acylaminosugars [SL01] 0.00% 0.21% NS
Other acyl sugars [SL05] 0.38% 0.00% ,0.0001
Flavonoids [PK12] 1.33% 8.39% ,0.0001
Fatty esters [FA07] 0.55% 0.24% NS
Results are expressed as percentage. Significant at P,0.05.
NE - not evaluated.
NS – not significant.
Common names used: (PC) Phosphatidylcholines, (PEt) Phosphatidylethonolamines, (PS) Phosphatidylserines, (PG) Phosphatidylglycerols, (PI) Phosphatidylenositos,
(PAc) Phosphatidic acid, (TG) Triradylglycerols, (SM) Sphingomyelins.
doi:10.1371/journal.pone.0110747.t002
Figure 2. Lipid composition detected in plasma from control and preeclamptic patients. Comparison of relative distribution of main class
of lipids in plasma of normal (A) and preeclamptic (B) patients, established by the area of the peaks obtained for the main lipids identified. N= 10 in
each group. [GP03]-(PS): Glycerophosphoserines or Phosphatidylserines; [GP02]-(PEt): Glycerophosphoethanolamines or Phosphatidylethonolamines;
[PK12]-(FLV): Flavonoids; [GP01]-(PC): Glycerophosphocholines or Phosphatidylcholines.
doi:10.1371/journal.pone.0110747.g002
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Experiments on hypertensive mice have showed significant
increase in SM [50]. Apparently it is involved in processes of
endothelial dysfunction, increased production of angiotensin II,
elevated levels of thromboxane A2 and hence hypertensive
disorders, which could explain its exclusively occurrence in the
population of patients with preeclampsia [50–52]. The predom-
inant lipid in preeclampsia placental samples was PS, and this
aspect can be correlated with the oxidation process.
The Flavonoids are known for their antioxidant properties
[53,54]. These lipids are not present in mammalian lipid
composition, and their presence in our study is probably derived
from the diet. These lipids interact in the signaling pathways of
apoptotic processes, operating in both promotion and inhibition
[55,56]. Evidences support the Flavonoids as protective factors
against cardiac ischemic [57,58]. In our study, we found a
reduction in the amount of Flavonoids in samples of placentas
from patients with preeclampsia when compared to controls. This
did not happen when we performed the analysis of plasma samples
that identified an increase of these lipids in patients with
preeclampsia.
The Macrolides polyketides-lactone-PK04 have shown greater
incidence in placental samples of preeclampsia group. They are
not a natural part of mammalian lipid composition and they can
be found in bacteria, fungi and plants. Rapamycin, also called
Sirolimus, is an important and known polyketide with many
biological and pharmacological activities, including antifungal,
immunosuppressive, antitumor, neuroprotective and antiaging
activities [59–63]. Recently, rapamycin has attracted interest for
the clinical treatment of organ transplant rejection and autoim-
mune diseases [64].
Table 3. Main classes of lipids in placental samples.
Placenta Group P
[Main class]-(Common name) Control (n = 10) Preeclampsia (n =10)
Glycerophosphocholines [GP01]-(PC) 0.00% 0.02% NE
Glycerophosphoethanolamines [GP02]-(PEt) 9.69% 0.00% ,0.0001
Glycerophosphoserines [GP03]-(PS) 34.85% 56.28% ,0.0001
Glycerophosphoglycerols [GP04]-(PG) 13.57% 1.92% ,0.0001
Glycerophosphoinositols [GP06]-(PI) 13.28% 4.39% ,0.0001
Glycerophosphoinositol monophosphates [GP07] 0.57% 0.00% ,0.0001
Glycerophosphates [GP10]-(PAc) 1.30% 0.24% NS
Diradylglycerols [GL02]-(DG) 7.73% 1.10% ,0.0001
Triradylglycerols [GL03] 1.04% 0.08% ,0.0001
Neutral glycosphingolipids [SP05] 0.07% 0.00% NE
Acidic glycosphingolipids [SP06]- (GM3) 0.26% 0.06% ,0.0001
Sterols [ST01] 0.00% 0.12% NS
Steroid conjugates [ST05] 1.68% 0.00% ,0.0001
Other acyl sugars [SL05] 0.42% 0.04% ,0.0001
Flavonoids [PK12] 11.68% 2.98% ,0.0001
Macrolide lactone polyketide [PK04] 3.86% 32.77% ,0.0001
Results are expressed as percentage. Significant at P,0.05.
NE - not evaluated; NS – not significant.
Common names used: (PC) Phosphatidylcholines, (PEt) Phosphatidylethonolamines, (PS) Phosphatidylserines, (PG) Phosphatidylglycerols, (DG) Diradylglycerols; (PI)
Phosphatidylenositos, (PAc) Phosphatidic acid, (TG) Triradylglycerols, (SM) Sphingomyelins, (GM3) Gangliosides.
doi:10.1371/journal.pone.0110747.t003
Figure 3. Lipid composition detected in placenta from control and preeclamptic women. Comparison of relative distribution of main class
of lipids in placenta of normal (A) and preeclamptic (B) patients, established by the area of the peaks obtained for the main lipids identified. N = 10 in
each group [GP03]-(PS): Glycerophosphoserines or Phosphatidylserines; [PK04] = Macrolide and lactone polyketides; [PK12]-(FLV): Flavonoids; [GP02]-
(PEt): Glycerophosphoethanolamines or Phosphatidylethonolamines; [GP06]-(PI): Glycerophosphoinositols or Phosphatidylinositols; [GL02]-(DG):
Diradylglycerols; [GP04]-(PG): Glycerophosphoglycerols or Phosphatidylglycerols.
doi:10.1371/journal.pone.0110747.g003
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Rapamicyn use has been associated with the development or
exacerbation of proteinuria [65–67]. The pathogenesis of
proteinuria is likely multifactorial and may involve tubular and
glomerular contributions. Recent data derived from biopsy sub
studies of clinical trials, which compared cyclosporine with
rapamycin, demonstrated that rapamycin use is associated with
tubular damage and tubular proteinuria [68]. In the glomerular
compartment, other ones have demonstrated reduced nephrin
expression [69] and reduced VEGF, particularly in patients with
significant proteinuria [70,71].
The immunosuppressive effects of rapamycin result from its
ability to inhibit proliferation by interfering with the function of
the mammalian target of rapamycin (mTOR) [72]. mTOR is a
serine/threonine protein kinase which controls the cellular
processes of growth, proliferation, transcription, protein biosyn-
thesis and ribosomal biogenesis [59,73]. mTOR exists in two
distinct protein complexes referred to as mTOR complex 1 and
mTOR complex 2. The inactivation of mTOR complex 1 kinase
activity by rapamycin results in the inhibition of the activities of
ribosomal S6 kinase and the eukaryotic translation initiation factor
4E-binding proteins, which have roles in ribosome biogenesis and
protein translation, respectively. In contrast, apoptosis and
autophagy are also stimulated by rapamycin [72,74].
Studies in immortalized cell lines originating from human
trophoblast suggest a key role for mTOR in the regulation of
trophoblast proliferation and it is suggested that the mTOR
pathway is a regulator of invasive trophoblast differentiation
[75,76]. In the mature placenta mTOR is expressed at the mRNA
level, however, the cellular localization of mTOR and the
functional role of this signaling pathway in the placenta after
implantation and early placental development remains unknown
[75,77,78].
Our study did not include other groups, such as gestational
hypertension or intrauterine growth restriction, which would be
important to evaluate the specificity of this association. In addition
it would be interesting to compare the lipid profile between obese
pregnant patients with normal outcomes and patients with
preeclampsia with and without obesity to better understand if
the lipid changes are a reflection of obesity, increased BMI or true
PE.
Conclusion
We identified a different pattern of lipids and distinct
concentrations of some lipid species in plasma and placenta
samples of preeclamptic patients. Further studies are needed to
clarify if these changes are specific to preeclampsia and whether
and how they could be related to its pathogenesis.
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